TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04189120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia , superficial serratus plane block and deep serratus plane block
Description: neuroaxial thoracic epidural analgesia and regional analgesia supeficial and deep serratus plane blocks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia , superficial serratus plane block and deep serratus plane block
Description: neuroaxial thoracic epidural analgesia and regional analgesia supeficial and deep serratus plane blocks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia , superficial serratus plane block and deep serratus plane block
Description: neuroaxial thoracic epidural analgesia and regional analgesia supeficial and deep serratus plane blocks
Study: NCT01712568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product (Ropinirole)
Description: one Tablet at 0 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product (Ropinirole)
Description: one Tablet at 0 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Product (REQUIP )
Description: one Tablet at 0 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Product (REQUIP )
Description: one Tablet at 0 hour
Study: NCT01201694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surface-Controlled Water Soluble Curcumin
Description: Starting dose 100 mg by mouth two times a day of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surface-Controlled Water Soluble Curcumin MTD
Description: Dose will be maximum tolerated dose (MTD) from Arm 1.
Study: NCT03434145

Intervention type: OTHER
Intervention: ophthalmologic exams
Description: ophthalmologic exams such as vision, intraocular pressure, axial length and optical coherence tomography
Study: NCT01097694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib mesylate
Description: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
Study: NCT00708097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaF
Description: Fluoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaF
Description: Fluoride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaF
Description: Fluoride
Study: NCT03511118

Intervention type: DRUG
Intervention: oxycodone
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: azithromycin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: escitalopram
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: sertraline
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study: NCT01097694

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00919516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell implantation
Description: Dual intramuscular and intra-arterial injections of bone marrow mononuclear cells harvested from the iliac crest. Injection sites are determined by location of stenosis and/or occlusion on angiogram obtained prior to implantation and typically occur in three medial and three lateral sites approximating the disease location.
Study: NCT01863433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Study: NCT06116396

Intervention type: GENETIC
Intervention: Genetic analysis on isolated cells
Description: Isolation of cells from blood and urine

Intervention type: GENETIC
Intervention: Genetic analysis on isolated cells
Description: Isolation of cells from blood and urine
Study: NCT03511118

Intervention type: DRUG
Intervention: ondansetron
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Ciprofloxacin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Doxycycline
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Levofloxacin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Methylphenidate
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Sumatriptan
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Citalopram
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Cyclobenzaprine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Furosemide
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Gabapentin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Hydrochlorothiazide
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Hydroxyurea
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Rosuvastatin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Topiramate
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study: NCT00708097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaF
Description: Fluoride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaMFP
Description: Fluoride
Study: NCT03511118

Intervention type: DRUG
Intervention: Trazodone
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study: NCT05768620

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: This is the usual care used to train visuospatial processes
Study: NCT01191294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation teaching session
Description: Simulation-based, mastery learning educational intervention in visual screening for melanoma
Study: NCT03511118

Intervention type: DRUG
Intervention: Valganciclovir
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Venlafaxine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Verapamil
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Remdesivir
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Anakinra
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Tocilizumab
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Fluvoxamine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Amoxicillin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Bupropion
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Duloxetine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Hydrocodone
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Levetiracetam
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Paroxetine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: Buprenorphine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study: NCT02809326

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 17 week Exposure Therapy Control Arm
Description: 15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Management Therapy
Description: TMT consists of 29 treatment sessions administered over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during Social and Emotional Regulation (SER). Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive 3-Week Trauma Management Therapy
Description: Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
Study: NCT03015545

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paretic leg-control
Description: standing on the vibration platform, with no vibration signals delivered.
Study: NCT00178360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: During individual Music Therapy sessions, subjects will participate in a variety of active music-making opportunities, including: playing musical instruments, singing, improvising, learning relaxation techniques, song writing, and/or lyric analysis. The activities for each session will be determined by both subject and therapist, and will be selected based on preference, emotional state, and desired goals for the day.~Group music therapy sessions will focus on improving socialization, depression, and group dynamics. In this setting, the Music Therapist will choose from the following interventions:~* Group singing~* Group drumming~* Music assisted relaxation~* Group song writing~* Lyric analysis~* Improvisation~* Music with art
Study: NCT03015545

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paretic leg-WBV
Description: standing on the vibration platform, with WBV at 30Hz, 1.5mm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-paretic leg-control
Description: standing on the vibration platform, with no vibration signals delivered.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-paretic leg-WBV
Description: standing on the vibration platform, with WBV at 30Hz, 1.5mm.
Study: NCT03854435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rate assessment (stethoscope)
Description: Immediately after birth heart rate will be evaluated by auscultation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart assessment (umbilical cord palpation)
Description: Immediately after birth heart rate will be evaluated by palpation of the umbilical cord
Study: NCT00203242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depacon IV and Depakote ER
Study: NCT04960410

Intervention type: COMBINATION_PRODUCT
Intervention: Types and exposure of different air pollutants
Description: Types and exposure of different air pollutants in COPD patients' living and working environment

Intervention type: COMBINATION_PRODUCT
Intervention: Types and exposure of different air pollutants
Description: Types and exposure of different air pollutants in COPD patients' living and working environment
Study: NCT03708185

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Description: N/A: see arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: N/A: see arm description
Study: NCT01583543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 400mg PO BID Continuous
Study: NCT04160481

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FruitFlow
Description: 300mg tomato extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT01483690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2500 international units/m2/day IM or IV on days 10 and 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2500 international units/m2/day IM or IV on days 10 and 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally to all patients the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally to all patients the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35
Study: NCT00503438

Intervention type: DEVICE
Intervention: Salto Talaris Ankle
Description: Salto Talaris Anatomic Ankle total joint prosthesis
Study: NCT02746068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-02

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03392532

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B toric contact lenses with HYDRAGLYDE
Description: Silicone hydrogel soft contact lenses for astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B toric contact lenses with HYDRAGLYDE
Description: Silicone hydrogel soft contact lenses for astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B toric contact lenses
Description: Silicone hydrogel soft contact lenses for astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B toric contact lenses
Description: Silicone hydrogel soft contact lenses for astigmatism
Study: NCT04217785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optive, Ophthalmic Solution
Description: 6 drops per day, for 8 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Serum eye drops
Description: UCS eye drops (6 drops per day, for 8 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genteal lubricant gel
Description: Genteal lubricant gel (2 drops per day, for 8 weeks)
Study: NCT00978432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 10 mg/day for Part 1 of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 10 mg/day for Part 1 of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: 40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: 40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doublet (RAD001 and LBH589)
Description: RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
Study: NCT02172066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Study: NCT03659786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC-Test
Description: Classification of the oocyte/embryo based on the expression pattern observed in the cumulus cells
Study: NCT00749580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch NRTIs as a Backbone to Raltegravir
Description: This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA \<75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
Study: NCT05830903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-assisted occupational training
Description: VR-assisted occupational training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-assisted occupational training
Description: VR-assisted occupational training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-assisted occupational training
Description: VR-assisted occupational training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-assisted occupational training
Description: VR-assisted occupational training
Study: NCT04520893

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ventilator setting vcv with pause
Description: ventilator setting vcv with pause

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ventilator setting vcv
Description: ventilator setting vcv without pause

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ventilator setting pcv-vg
Description: ventilator setting with pcv-vg